Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.
XPON Technologies reports a modest 2% increase in martech revenue and a strong cash position for Q2 FY25, while navigating an 8% decline in annualised recurring revenue amid strategic sales recalibration.
Insignia Financial reported a robust 2.2% increase in Funds Under Management and Administration to $326.8 billion in 2Q25, underpinned by strong net inflows and strategic milestones including the IT separation from NAB and the unveiling of its Vision2030 growth strategy.
First Graphene Limited has responded to an ASX price query, attributing its recent share price and volume surge to increased buying activity in Germany linked to prior commercial announcements, while reaffirming full compliance with ASX disclosure rules.